Covid Vaccine Maker BioNTech To Build Factory In Singapore

The Singapore production site will be the German company's first mRNA manufacturing facility outside Europe, and will have an estimated capacity of several hundred million doses of such vaccines.

Covid jab maker BioNTech said Monday it would build a Southeast Asia headquarters and manufacturing site in Singapore to produce hundreds of millions of mRNA-based vaccines per year. Construction of the site will start this year, and it could become operational by 2023, the German company said in a statement. "With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world," said BioNTech chief executive Ugur Sahin. The vaccine produced by BioNTech jointly with Pfizer of the United States became the first Covid-19 jab to be approved for use in the West late last year.